As constituents of Averrhoa bilimbi leaves we identified three new compounds (1-3) together with 12 known ones (4-15); their inhibitory activities on cytochrome P450 3A4 (CYP3A4) and 2D6 (CYP2D6) were examined. Among the isolated compounds, the mixture of 1 and 2, and compounds 4 and 9 showed strong inhibition on CYP3A4, but mild or no inhibition on CYP2D6. These compounds revealed the characteristics of 1) time-and concentrationdependent inhibition, 2) requirement of NADPH for the inhibition, 3) no protection by nucleophiles, and 4) suppression of the inhibition by competitive inhibitor. Thus, they are suggested to be mechanism-based inactivators of CYP3A4 and CYP2D6. The kinetic parameters for the inactivation (k inact and K I ) were 0.19 min -1 and 36.7 M for the mixture of 1 and 2, 0.126 min -1 and 10.5 M for 4, and 0.29 min -1 and 23.4 M for 9.
Inhibition of CYP can result in an excessive increase in plasma concentration of drugs and in a reduction of clinical efficacy of prodrugs requiring metabolic activation. Thus, potential drug-drug interaction can cause serious side effects of co-administered drugs in clinical aspects. On the other hand, the inhibitor can be used as a drug-sparing agent, to decrease the doses and financial cost needed to maintain target concentration of expensive drugs [5] . CYP inhibitions are divided into reversible, quasi-reversible, and irreversible inhibitions. In irreversible inhibition, being referred also as "mechanism-based inactivation", the inactivator binds to the enzyme and chemically transforms it into an inactivated species, resulting in irreversible inhibition [6] . This type of inhibition completely inactivates the drug-metabolizing enzyme and causes serious adverse effects, which might persist even after withdrawal of the inhibitor. Of course, the inactivated enzyme will be reproduced, but this process must take several days or, at least several hours, to recover the enzyme activity to the sufficient level.
Likewise, interactions between herbs and drugs can also increase or decrease the pharmacological and toxicological effects of either component. The herb-drug interaction is especially important in the case of long-term medication. For example, synergic therapeutic effects may complicate the dosing of long-term medication, such as herbs traditionally used to decrease glucose concentration in diabetes, and could theoretically cause hypoglycemia if taken in combination with conventional drugs [7] . His research lab at Hokuriku University started in April, 2014 and focuses on identifying active constituents (especially anticancer constituents) in traditional medicines in Japan, China, Indonesia, and so on. Averrhoa bilimbi L., known as "blimbing wuluh" in Indonesia, has a considerable medical reputation as a folk remedy for the treatment of diabetes mellitus [8] and an in vivo effect and anti-diabetic mechanism were also reported [8, 9] . A. carambola (starfruit), a congener of A. bilimbi, was reported to inhibit CYP3A4 [10] , but no work has been reported on the potency of A. bilimbi causing herbdrug interactions mediated by CYP. When studying the CYP inhibitory constituents of Indonesian medicinal plants we examined the CYP3A4 and/or CYP2D6 inhibitory constituents of A. bilimbi.
The 70% EtOH extract of A. bilimbi leaves inhibited CYP2D6 selectively (IC 50 against CYP2D6, 23.1 g/mL; CYP3A4, >100 g/mL), but the n-hexane and EtOAc fractions prepared from the extract inhibited both CYP3A4 (IC 50 value: n-hexane fraction, 0.22 g/mL; EtOAc fraction, 27.2 g/mL) and CYP2D6 (IC 50 value: n-hexane fraction, 1.29 g/mL; EtOAc fraction, 3.64 g/mL). Thus, these fractions were subjected to further separation and the n-hexane fraction gave three known compounds (4-6), together with fatty materials, whereas the EtOAc fraction gave three new compounds (1-3) together with 12 known ones (7-15). The structures of the 13 known compounds, by comparing their spectral data with those reported and/or of authentic samples, were determined as: -amyrenone (4) [11] , -amyrin (5) [12] , phytol (6) [13], -sitosterol (7) [14, 15] , stigmastanol (8) [14] , aurantiamide benzoate (9) [16] , trans-cinnamic acid (10), 4-hydroxycinnamic acid (11) [17] , phloretic acid (12), (S)-dehydrovomifoliol (13) [18] , (6S,7aR)-loliolide (14) [19] , and carambolaflavone (15) [20] .
Compounds 1 and 2 were obtained as an inseparable mixture (ca. 1:1) with yellow color. The HRFABMS data indicated the molecular formula C 28 H 32 O 13 and the UV spectrum showed absorptions characteristic of flavones at 214.5, 272, and 333.5 nm [21] . The 1 H and 13 C NMR spectra of the mixture indicated the presence of two sets of signals, which were assigned to each isomer by careful analysis of the COSY, HMQC, and HMBC spectra. The assigned 1 H and 13 C NMR data ( Table 1) were similar to those of the known flavone C-glycoside, carambolaflavone (15) [20] , obtained from the same extract. However, the data of 1 and 2 indicated that they have an additional methoxy group (1,  H 3.97,  C 56.7; 2:  H 3.99,  C 57.6). The location of the methoxy group was determined to be at C-7 based on the low-field shift of C-7 (1:  C 165.2, 2:  C 166.6, 15:  C 162.5) and the high-field shift (1:  C 91.7, 2:  C 92.2, 15:  C 94.4) of C-8. Thus, 1 and 2 were 7-O-methyl derivatives of a flavone C-glycoside similar to 15.
The sugar units were determined to be an -rhamnopyranose and a -fucopyranose based on the coupling constants and the 13 C NMR chemical shift values deduced by the analyses of the COSY and HMQC spectra. The location of the -fucopyranose unit was CYP3A4 and/or CYP2D6 inhibitory constituents of Averrhoa bilimbi Natural Product Communications Vol. 10 (1) 2015 59
Compound 3 showed the molecular formula C 26 . These spectral data were similar to those of a dihydrochalcone glucoside isolated from Lithocarpus litseifolius [22] . The analyses of the COSY and HMQC spectra and comparison with literature data [23] indicated the sugar moieties to be -arabinofuranose and -fucopyranose. The HMBC correlations and the NOEs indicated the locations of the -arabinofuranose and -fucopyranose units to be at C-5' and at C-2', respectively ( Figure  2 ). Thus, compound 3 was determined as 2'
The isolated compounds comprised flavonoid glycosides (1, 2, 15), a dihydrochalcone glycoside (3), triterpenes (4, 5, 7, 8), a diterpene alcohol (6), a modified dipeptide (9), three phenylpropanoids (10-12), and two C 13 -norisoprenoids (13, 14) . These compounds were tested for their inhibitory activity on CYP3A4 and CYP2D6 ( Table  2) . Compounds 4 and 9 displayed the most potent inhibition against CYP3A4 (IC 50 , 6.01 M and 5.98 M, respectively), followed by the mixture of 1 and 2 (IC 50 , 16.9 M). On the other hand, against CYP2D6 only the mixture of 1 and 2 and compound 3 exhibited a mild inhibition (IC 50 , 15.5 M and 25.7 M, respectively). Next, we examined the possibility of mechanism-based CYP3A4 inhibition of the mixture of 1 and 2, and compounds 4 and 9. As shown in Figure 3 , the mixture of 1 and 2, and compounds 4 and 9 increased their inhibitory activity compared with that without preincubation. The residual CYP3A4 activities after 20 min preincubation with them were 11%, 3%, and 7%, respectively, compared with those without preincubation. This is similar to troleandomycin, the known mechanism-based CYP3A4 inhibitor [24] , while ketoconazole, a competitive inhibitor [25] , did not show any increase in the CYP3A4 inhibitory activity. Mechanism-based inactivation requires a catalytic step for the conversion of the inactivator to a reactive intermediate, which was indicated by the requirement of NADPH. The residual activity of CYP3A4 in the presence of the mixture of 1 and 2, and compounds 4 and 9 was decreased with preincubation time-dependently only in the presence of NADPH like the positive control, troleandomycin ( Figure 4 ).
The metabolic inactivator is also converted into an activated form, but it can be distinguished from the mechanism-based inhibition by examining the effect of a nucleophile. In the case of a metabolic inactivator, the metabolite departs from the active site of the enzyme and then returns to inactivate the enzyme [26] . Therefore, the coexisting nucleophiles compete with the metabolite of the inhibitor to protect the enzyme from inactivation of the released metabolite. On the other hand, the protective effect of the nucleophile is not observed in the mechanism-based inhibition because the metabolite is not released from the enzyme. With the tested compounds 1/2, 4, and 9, a protective effect of N-acetylcysteine (nucleophile) was not observed, even with a bulky thiol (GSH), which was the same as in the case of troleandomycin ( Figure 5 ). Thus, once the reactive intermediate has been generated, it should not leave the active site. Moreover, a competitive inhibitor protects inhibition by a mechanism-based inactivator. When a competitive inhibitor is added concomitantly with a mechanism-based inhibitor, the competition for binding at the active site prevents the formation of an enzyme-inhibitor complex and decreases the rate of inactivation [6, 27] . The mixture of 1 and 2, compound 4 or 9, or troleandomycin was thus incubated with human liver microsomes in either the absence or presence of ketoconazole, a competitive inhibitor of CYP3A4. After normalization of the residual activity against that at preincubation time of 0 min (100%), the residual activities after 20min preincubation were increased from 63%, 27%, and 10% in the absence of a competitive inhibitor, ketoconazole, to 89%, 34%, and 58% in the presence, which was similar to the inhibition by a mechanism-based inhibitor, troleandomycin ( Figure 6 ).
Based on these characteristics: 1) time-dependent inhibition, 2) requirement of NADPH, 3) no affect by nucleophiles, and 4) protection by a competitive inhibitor [6] , compounds 1, 2, 4, and 9 were concluded to be mechanism-based inhibitors of human liver microsomal CYP3A4 activity.
Two principal kinetic parameters that are specific for mechanismbased inhibitors are the maximal rate constant of inactivation (k inact ) and the inactivator concentration required for half-maximal inactivation (K I ) [6, 28] . These kinetic parameters (k inact and K I ) for inhibition by 1/2, 4, and 9 were 0.19 min -1 and 36.68 M for 1/2, 0.126 min -1 and 10.52 M for 4, and 0.29 min -1 and 23.40 M for 9. The efficiency of enzyme inactivation determined from the ratio of k inact to K I was 5.2, 12.4, and 12. 4 for 1/2, 4, and 9 . These values are not as high as those reported for GF-I-1 (161.29) and GF-I-4 (384.62), the strong mechanism-based inactivator reported from grapefruit juice on testosterone 6-hydroxylation mediated by human liver microsomes [29] . However, this value is comparable with those of mechanism-based inactivators from herbs reported for bergamottin (2.0), 6',7'-dihydrobergamottin (2.71), glabridin (20) , limonin (11.47), rutaecarpine (3.59), and 5-methoxypsoralen (5.8) [29, 30] .
Experimental
General: Optical rotations were measured on a JASCO DIP-140 digital polarimeter and UV spectra were obtained using a Shimadzu UV-160A spectrophotometer. HRFABMS was carried out on a JEOL JMS-700T spectrometer using glycerin as a matrix and NMR spectra were from a JEOL JNM-LA400 spectrometer with TMS as an internal standard. Medium pressure liquid chromatography (MPLC) was performed using a Büchi MPLC system with a normal phase column (Silica gel 60N, 40-50 m; Kanto Chemical Co., Inc., Tokyo, Japan). Analytical and preparative TLC was carried out on precoated silica gel 60F 254 and RP-18F 254 plates (0.25 or 0.50 mm thickness; Merck, Whitehouse Station, NJ, USA). 
Chemicals and biochemical: Baculovirus-insect cells-expressed

Extraction and isolation:
A. bilimbi leaves (2.5 kg) were powdered and macerated with 70% EtOH (10 L, 24 h, × 3). Each extract was filtered and evaporated under reduced pressure, followed by lyophilization, to give a 70% EtOH extract (500 g). This was successively partitioned with n-hexane, EtOAc, and n-BuOH (each 3 L, × 3) to yield n-hexane (10 g), EtOAc (49 g), n-BuOH (110 g), and aqueous fractions (287 g). The n-hexane fraction was subjected to MPLC on silica gel (4.9 cm i.d. × 23 cm, flow rate 10 mL/min) with a CH 2 Cl 2 -MeOH gradient system (100:0-70:30) to give 13 fractions (FH1-13). FH3 [CH 2 Cl 2 eluate, 100 mL, 157 mg] was subjected to normal-phase pTLC with CH 2 Cl 2 -MeOH (99:1) to give 4 (2.3 mg). FH 6 [CH 2 Cl 2 -MeOH (98:2) eluate, 100 mL, 71 mg] was subjected to normal-phase pTLC with CH 2 Cl 2 -MeOH (99:1) to give 5 (2.0 mg) and 6 (2.0 mg). The EtOAc fraction was subjected to MPLC on silica gel (4.9 cm i.d. × 23 cm, flow rate 10 mL/min) with a n-hexane-EtOAc gradient system (100:0-0:100) to yield 13 fractions (FE1-13). FE1 [n-hexane eluate, 400 mL, 371 mg] was separated using MPLC on silica gel (4 cm i.d. × 7.5 cm, flow rate 10 mL/min) with a n-hexane-EtOAc solvent system to give 5 (4.7 mg). FE3 [n-hexane-EtOAc (20:80) eluate, 100 mL, 164 mg] was separated with normal-phase pTLC on n-hexane-EtOAc mM sodium citrate, 20 mg/mL NADP + , 20 mg/mL G-6-P, 13.3 mg/mL MgCl 2 ·10H 2 O) and 2 L of inactivators incubated for 10 min at 37°C. Ketoconazole and quinidine were used as positive control for CYP3A4 and CYP2D6, respectively. The reaction was initiated by the addition of 100 L of enzyme/substrate mix in phosphate buffer pH 7.4 (2 M of cDNA-expressed CYP3A4 or CYP2D6, 15 mg/mL insect cell control protein, 50 mM 7-BFC or 10 mM AMMC) and continuing with incubation at 37°C for 30 min. The reaction was stopped by the addition of 80 L of 20% 0.5 M Tris base and the fluorescence was measured using a Perkin Elmer HTS 7000 bioassay reader with excitation and emission wavelength at 405 and 535 nm for CYP3A4 and 390 and 465 nm for CYP2D6. The assay was performed in triplicate for all specimens.
Time-dependent inhibition for CYP3A4:
The effect of preincubation time on CYP inhibition was determined by preincubating 2 L of sample with 80 L CYP3A4 enzyme system (phosphate buffer, 0.5 M, pH 7.4; insect cell control protein; cDNAexpressed CYP3A4) for 0, 5, 10, 15, and 20 min at 37°C in the presence of 98 mL cofactor mix. Substrate solution (20 L) was added and incubation was continued for 30 min. Troleandomycin (5 M) and ketoconazole (0.5 M) were used as positive and negative control. All incubations were performed in triplicate and the remaining activity was analyzed using Excel spreadsheet (Microsoft Corporation, USA).
Effect of NADPH, nucleophiles and competitive inhibitor on inhibition of CYP3A4:
The effect of NADPH on CYP3A4 inactivation was determined by preincubating 2 L of sample with 98 L cofactor mix (with the presence or absence of NADPH) and 80 L CYP3A4 enzyme system (phosphate buffer, 0.5 M, pH 7.4; insect cell control protein; cDNA-expressed CYP3A4) for 0, 5 10, and 20 min at 37°C. Substrate solution (20 L) was added and incubation was continued for 30 min. The addition of 80 L of 80% Tris base/MeOH stopped the reaction and the remaining activity was calculated. The effects of trapping agents was determined by preincubating 2 L of sample with 80 L CYP3A4 enzyme system and 98 L cofactor mix with the addition of 5 mM of trapping agent (GSH or N-acetyl-L-cysteine) in the presence of NADPH, preincubated for 0 and 20 min at 37°C. The effect of the competitive inhibitor was determined in the same way as with the trapping agents effect using ketoconazole 0.5 M with the preincubation times of 0, 5, 10, and 20 min. Values are presented as a percentage of the activity observed at 0 min which was arbitrarily set as 100%.
Calculation of kinetic constants:
The slopes were obtained from linear regression of log percentage of remaining activity versus time plots at each concentration. The first order inactivation constant (k app ) at each inactivator concentration was obtained by multiplying the slope obtained from the linear regression analysis by 2.303. The inactivation rate constant at infinite concentration of inhibitor (k inact ) and the inhibitor concentration required for half-maximal rate for inactivation (K I ) were calculated from the double reciprocal plots of k app versus sample concentration by linear regression analysis. The y-intercept is known to be equal to 1/k inact , while the x-intercept equals −1/K I .
